Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE study in metastatic or recurrent esophageal cancer
jRCTs031180143Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cisplatin and fluorouracil in esophageal cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: overall survival. Started Sep 2014; status: completed.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs031180143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180143.